Algo, a leading innovator in end-to-end supply chain optimization software based in Troy, MI, announced today that it received a multi-million dollar investment from Plymouth Growth, a growth equity firm based in Ann Arbor, MI. This new capital and strategic partnership will allow Algo to deepen its market penetration and increase sales and marketing capabilities.
Algo is a high-growth, SaaS solution provider used by enterprise businesses, including many Fortune 500 companies. Algo’s platform utilizes machine learning, optimization and other Artificial Intelligence (AI) methods, to analyze, drive, predict, and prescribe critical business insights and perform functions, including demand and inventory planning, sales forecasting, product lifecycle management, and category optimization. Algo’s customers interact with Algo’s virtual supply chain analyst through natural language to increase sell-in and sell-through, optimize inventory, minimize returns, and drive various other forms of measurable ROI across the extended enterprise.
“We are excited to double down on the success we’ve seen over the past few years and accelerate that further with Plymouth Growth by our side,” said Amjad Hussain, CEO and Founder of Algo. “Plymouth’s deep industry knowledge and breadth of experience is the key reason we chose them to join our journey. We believe the time is now to transform the supply chain industry. We at Algo have innovative technology that is changing the way the industry manages demand and inventory planning.”
“Global enterprises with complex supply chains are benefiting from the value of Algo. Once customers experience the power of Algo’s AI-based and data-driven approach to predictive and prescriptive supply chain optimizations, there is no going back,” said Kevin Terrasi, Partner at Plymouth Growth. “It is clear that Algo’s groundbreaking technology is going to disrupt the supply chain industry permanently.”
David Warrick, General Manager of Global Supply Chain at Microsoft and Algo customer shared this view when he noted, “The landscape of supply chain is changing rapidly. It is our partnership with companies like Algo that will continue to define the future.”
“Algo is humbled by David’s comments and the evolving partnership with Microsoft,” said Hussain. “Algo’s cooperative approach in redefining the supply chain industry, alongside key industry leaders like Microsoft, will continue to drive broad industry impact.”
With Plymouth’s investment, Kevin Terrasi will join Algo’s Board of Directors. “We couldn’t be more excited to be a part of Algo’s journey,” said Terrasi.
Algo is a Troy, MI-based supply chain SaaS platform that enables automated, data-driven workflows and business insights to enterprises. Its sophisticated virtual supply chain analyst, powered by AI, AR, and NLP, provides value creation to various verticals, including retailers, distributors, and manufacturers. The Company’s deep domain knowledge of both technology and supply chain allows the team to rapidly train Algo’s solution on analytically rich workflows and business functions. With an easy-to-use conversational interface, Algo is bringing “plain” language understanding, machine learning, and robust optimization to life within organizations, while creating an agile way to increase revenue and profitability.
About Plymouth Growth
Plymouth Growth invests in mid-continent B2B software and technology companies – with proven business models, rapid growth, and strong teams – that are ready to scale. The Plymouth team brings decades of experience as operators, advisors, and investors, and understands that while metrics matter, it’s people that are critical to growth. We look beyond the numbers to understand businesses, teams, and cultures, and we seek to partner with entrepreneurs that have accomplished a lot with a little. Based in Ann Arbor, MI and actively investing out of its fifth fund, Plymouth Growth helps teams achieve smart, proven growth.
ComplySci Announces $120 Million Growth Investment From K1 Investment Management
ComplySci, the leading provider of regulatory technology and compliance solutions for the financial services sector, announced today that it has received a growth capital investment of approximately $120 million from K1 Investment Management, a leading private equity investment firm focused on high-growth enterprise software companies.
ComplySci is a widely recognized leader in offering innovative compliance software that creates a robust employee compliance function. The company’s solutions deliver scalable identification and mitigation of employee regulatory and compliance risks, at a high degree of precision and on a cost-efficient basis.
ComplySci partners closely with C-suite teams as well as in-house compliance, legal and technology professionals to deliver technology-enabled employee compliance solutions for broker-dealers, registered investment advisers (RIAs), hedge funds, private equity firms, investment advisors, venture capital firms and other businesses across the financial services sector.
Amy Kadomatsu, Chief Executive Officer of ComplySci, said, “We are thrilled that K1 shares our passion about the opportunities ahead for our business and our excitement around the future of innovation in the RegTech industry. With K1 as our partner, ComplySci looks forward to continuing to build out our products and services, and to driving additional growth through acquisitions. This investment underscores the enormous momentum that ComplySci has generated as the leading provider of innovative technology-driven employee compliance solutions across the financial services sector.”
$120 Million Investment Supports Ongoing Robust Growth
ComplySci will leverage K1’s investment to further build out its platform including existing modules, such as Political Contributions Verification, Senior Managers and Certification Regime, and Compliance Program Management and the recently-launched Compliance Control Room and Conflict Checking products, which track firm activities along with employee activities to proactively identify potential conflicts of interest and market abuse through a single integrated solution.
“As reflected in our record financial results for the first quarter of this year, which represented a new high-water mark for our already rapidly growing firm, we are leaders in a fintech segment where proven solutions from experienced providers are always in demand, regardless of market, economic or industry cycles,” stated Ms. Kadomatsu. “For our customers, business partners and employees, our new partnership with K1 underscores this key take-away: The best is yet to come as we harness the significant new investment in our company with the talent, energy and innovative spirit that our entire team brings to each customer relationship. We are setting the standard for the future of tech-empowered employee compliance.”
Existing investors in ComplySci will retain their stakes in ComplySci following K1’s investment.
K1 Expands Reach in Fintech Software
K1 has established itself as a leading investor in the enterprise software and software-as-a-service (SaaS) sectors, combining proprietary transaction sourcing capabilities with the experience and expertise of its operations team, K1 Operations, LLC. The firm has a robust track record in partnering with enterprise software providers including Smarsh, Digital Reasoning, Entreda, FMG Suite, and others to drive substantial growth in the wealth management space, an area where K1 believes particularly strong expansion opportunities exist for ComplySci.
Roy Liao, Senior Vice President at K1 Investment Management, said, “In this environment of ever-expanding regulatory complexities, financial services firms recognize how crucial it is to have technology-enabled, sophisticated and reliable employee compliance solutions. ComplySci has successfully positioned itself as a leading and trusted partner to these firms, providing them with indispensable capabilities that give them the visibility and confidence they need to operate their businesses, on a scalable yet effective basis. We’re delighted to partner with Amy and the ComplySci team to further expand the company’s ongoing growth and success.”
14 Things You Can Learn From the World’s Top Investors
When it comes to building a portfolio that exceeds expectations, we think that everyone could benefit from taking a look at the lessons we can learn from great investors.
Rather than copy what investors have done, we recommend applying their principles to your life, taking into account the amount of risk you want to take, and the profit goals you want to achieve.
We recommend following billionaire investor Jim Rogers’ advice, to only invest in things you understand. So, while at some point you might be comparing, say, gold to real estate and stocks, you should stick with what you have at least a basic knowledge of.
1. Invest Long-Term
Unlike day trading, where short-term gain is the goal, reaping significant rewards typically comes from long-term investing.
Consider: When Amazon first went public in May 1997, shares cost $18. Since then, shares have undergone three stock splits (between 1997 and 1999). If you had purchased just ten shares when Amazon first went public (for a total cost of $180), your shares would be worth over $230,000 today.
Yes, Amazon is an exceptional story, but there are lessons to be gleaned from this company. The value of a share issued during its IPO has skyrocketed, but it didn’t do so overnight. Rather, it took 25 years. People would do the best investing for the long-term, letting their holdings ride out any blips in value.
In Amazon’s case, the company has seen steady growth most years, but there was a major decline in value around 2005, and most of the value seen today was gained after twenty years of existence.
2. Verify Your Hunches
Legendary stock trader Jesse Livermore argued that, no matter how much you think you know, you must let the market verify your hunches. Only then, should you make any moves (but when you do, move quickly).
3. Evaluate Prices as Fair or Not Fair — Not Good or Bad
As the world’s most successful investor in history, there’s a lot you can learn from Warren Buffet.
One of his most well-known teachings is summarized in the following adage: “It’s far better to buy a wonderful company at a fair price than a fair company at a wonderful price.”
There are two things to take away from this quotation. First, the company itself matters more than whether the price is good or not. Second, when determining whether you should purchase shares, you should consider the price in terms of how fair it is, not how good it is based on other metrics.
So, how do you evaluate a company? First, understand its quality by looking at balance sheets and understanding its management team and its practices. Second, evaluate the price based on your findings.
4. Be Frugal and Pinch Your Pennies
Jack Bogel, the founder of the Vanguard Group (known for its low-cost mutual funds) has flown first-class only once, and only because he got the upgrade for just $50. Despite having deep pockets, Bogel pinched pennies.
You can see this approach in the way that many of Vanguard’s mutual funds are structured. Many charge less than 0.2% per year, while equity funds (on average) charge more than 1%.
5. Buy High and Sell Higher
You’ll often hear the phrase, “buy low, sell high,” but investor Dennis Gartman argues that what you should do instead is buy high and sell higher. This is because Gartman argues that you can’t know when a price is low, nor can you know when a price is high.
As such, you want to buy into opportunities when they present themselves. Try to identify strengths and flaws in a company rather than whether a price is low or high.
6. Buy Assets Trading Below Their Intrinsic Value
Buying assets that are currently trading below their intrinsic (or book) value was a principle frequently espoused by the father of value investing, Benjamin Graham, who eventually became a mentor to Warren Buffet.
Graham argued that the markets tend to overreact in both directions, leading to prices that don’t necessarily reflect how sound the company’s financial fundamentals are.
By identifying those that are undervalued and underestimated, you stand to increase your profit potential.
7. Be Humble
Investor Bill Gross maintains a humble attitude despite his successes; overconfidence (and its opposite, underconfidence) can be detrimental to making the best decisions and taking the best course of action.
Furthermore, humility allows you to admit when things have gone horribly wrong. Doing so is the first step toward learning from your mistakes and improving in the future.
8. Be Patient
One of the things you’ll notice when reviewing Carl Icahn’s portfolio is that he’s been patient for a long time.
Being inpatient and acting impulsively can lead to poor decision making, but that doesn’t mean there isn’t room for decisive action. Rather, be patient, and when the right opportunity comes along, act accordingly.
9. Big Winners Overwhelm Losers
According to Peter Lynch, you only need a couple of great investments in your lifetime. These big winners will more than offset all of your losses.
10. Learn from the Past
Lots of investors say that they learn from their mistakes, and John Neff is no different. Neff, who is one of the most successful investors in the world, credits the success of his Windsor Fund. He said that investors needed to be students of history without being a captive of it:
At least a portion of Windsor’s critical edge amounted to nothing more mysterious than remembering lessons of the past and how they tend to repeat themselves.
11. Invest in a Company During Its Early Stages
Thomas Rowe Price Jr, who would start the company known today as T Rowe Price, argues that the best time to begin investing in a company is during its early growth stages.
This is an integral pillar of his Growth Stock Philosophy. Early investment, however, requires that you do fundamental research, including interviewing a company’s management before purchasing the company’s stock.
12. Make Money During Downturns
Carlos Slim Helu is one of the richest men in the world, and he made a sizable portion of his fortune during one of Mexico’s hardest economic recessions. You can follow a similar principle by identifying healthy companies.
Because all companies are likely to be negatively affected, focusing on the price may not be supremely helpful when identifying such companies. These otherwise healthy companies will likely be undervalued as every economic participant maintains a negative outlook.
13. You Can Focus on the Short-Run
Many of the investors we’ve featured focused on the long run, but George Soros differs in that he focuses on short-term speculation. If you’re comfortable taking a big picture, macroeconomic look, you can make bets on the movement of various assets, including currencies.
There’s an element of reflexivity in Soros’ investments, and if you prefer to make short-term bets, learning from Soros’ investment philosophies might help you succeed.
14. Learn, Learn, and Learn Some More
When you look at John Templeton’s Sixteen Rules for Investment Success, you’ll see several common themes. One of them is that you should always be learning to maximize your success and profits from investing in the markets.
According to Templeton, those who aren’t curious or think they have the answers to everything will only meet failure when it comes to investment.
The markets are constantly changing, and there are always new things to learn to make sure that your portfolio is as good as it can be. This requires a fair amount of homework on your part, but it’s best to put in the work ahead of time to prevent future losses.
When you make mistakes, however, learn from them — don’t just keep making the same mistakes over and over again.
Everyone who participates in the stock market starts with a different budget and has different goals and risk tolerances.
As such, it can be a bad idea to copy others’ portfolios, even if that person is a highly successful investor. That doesn’t mean that there’s nothing for you to learn from these investors. We recommend listening to the principles they espouse to make sure that you work toward your own goals, not other people’s.
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across its six global manufacturing locations and add a new manufacturing facility in Europe.
The new manufacturing facility in Europe is expected to be operational by the end of 2023. The investment will also fund capacity expansion, new product innovations, manufacturing technology enhancements and business continuity improvements across its existing network, all designed to maximize supply and reduce risks for pharmaceutical companies that rely on ready-to-fill syringes for their injectable drugs — including complex biologics, vaccines and small molecules.
“BD invented the ready-to-fill, pre-fillable syringe technology, and today’s announcement demonstrates our continued commitment to better serve our customers,” said Eric Borin, worldwide president of BD Pharmaceutical Systems. “Since 2018, BD has added 350 million units of manufacturing capacity for glass barrel pre-fillable syringes, and this new commitment will invest in additional upgrades at all of our Pharmaceutical Systems manufacturing facilities and across multiple product categories. In addition, this investment positions BD to have the needed surge capacity for increased pre-fillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines. This significant investment in one of BD’s fastest growing business units will further advance our leadership position and enable continued strong growth in the years ahead.”
The six current manufacturing facilities for BD Pharmaceutical Systems that will see a portion of this investment include facilities in Columbus, Nebraska; Cuautitlán, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, United Kingdom; and Tatabánya, Hungary.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
Israeli Startup Infinipoint Launches First Device-Identity-as-a-Service (DIaaS) Solution
Post Investment from DIFC FinTech Fund, Legaltech Startup Clara Opens in Dubai
Doctor Troller Becomes Top 3 Richest NFT artist selling Crypto art With Net Worth of £200 Million GBP
Interview2 years ago
An Interview with Joel Arun Sursas, Head of Clinical Affairs at Biorithm, Singapore
More1 year ago
6 Promising Up and Coming Fashion Companies
More3 years ago
Factors to Consider When Planning Your Office Design and Layout
Interview1 year ago
An Interview with Russell Jack, Southland-based Yogapreneur and Mindfulness Teacher
Other Internet Tech3 years ago
How to become an IPTV reseller? A beginner’s guide
More3 years ago
IPTV business for beginners
Business Ideas3 years ago
50 Small Business ideas with low investment
More3 years ago
Advantages of Using Ride-hailing Services for Transportation